HDAC6 and Ovarian Cancer

被引:27
|
作者
Haakenson, Joshua [1 ]
Zhang, Xiaohong [1 ,2 ]
机构
[1] Univ S Florida, Morsani Coll Med, Dept Pathol & Cell Biol, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA
关键词
HDAC6; ovarian cancer; cancer-related signaling pathways; inhibitors; cell stress response; motility; oncogenesis; histone deacetylase; HISTONE DEACETYLASE 6; REGULATES AGGRESOME FORMATION; 2 CATALYTIC DOMAINS; CELL-MIGRATION; MICROTUBULE ACETYLATION; GLUCOCORTICOID-RECEPTOR; STRESS GRANULES; PROTEIN; TUBULIN; INHIBITORS;
D O I
10.3390/ijms14059514
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The special class IIb histone deacetylase, HDAC6, plays a prominent role in many cellular processes related to cancer, including oncogenesis, the cell stress response, motility, and myriad signaling pathways. Many of the lessons learned from other cancers can be applied to ovarian cancer as well. HDAC6 interacts with diverse proteins such as HSP90, cortactin, tubulin, dynein, p300, Bax, and GRK2 in both the nucleus and cytoplasm to carry out these cancerous functions. Not all pro-cancer interactions of HDAC6 involve deacetylation. The idea of using HDAC6 as a target for cancer treatment continues to expand in recent years, and more potent and specific HDAC6 inhibitors are required to effectively down-regulate the tumor-prone cell signaling pathways responsible for ovarian cancer.
引用
收藏
页码:9514 / 9535
页数:22
相关论文
共 50 条
  • [21] HDAC6 expression is correlated with better survival in breast cancer
    Zhang, ZH
    Yamashita, H
    Toyama, T
    Sugiura, H
    Omoto, Y
    Ando, Y
    Mita, K
    Hamaguchi, M
    Hayashi, S
    Iwase, H
    CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6962 - 6968
  • [22] HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights
    Passaro, Eugenia
    Papulino, Chiara
    Chianese, Ugo
    Toraldo, Antonella
    Congi, Raffaella
    Del Gaudio, Nunzio
    Nicoletti, Maria Maddalena
    Benedetti, Rosaria
    Altucci, Lucia
    CANCERS, 2021, 13 (24)
  • [23] Development of selective HDAC6 inhibitors to improve cancer immunotherapy
    Gajendran, Nithya
    Suresh, Manasa
    Quiceno, David
    Li, Xintang
    Durr, Marie
    Tan, Karen
    Noonepalle, Satish Kumar Reddy
    Villagra, Alejandro
    CANCER RESEARCH, 2024, 84 (06)
  • [24] A role for HDAC6 in leptin sensitivity
    Greenhill, Claire
    NATURE REVIEWS ENDOCRINOLOGY, 2022, 18 (04) : 194 - 194
  • [25] HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape
    Zamperla, Michela Gottardi
    Illi, Barbara
    Barbi, Veronica
    Cencioni, Chiara
    Santoni, Daniele
    Gagliardi, Stella
    Garofalo, Maria
    Zingale, Gabriele Antonio
    Pandino, Irene
    Sbardella, Diego
    Cipolla, Lina
    Sabbioneda, Simone
    Farsetti, Antonella
    Ripamonti, Chiara
    Fossati, Gianluca
    Steinkuhler, Christian
    Gaetano, Carlo
    Atlante, Sandra
    CLINICAL EPIGENETICS, 2024, 16 (01)
  • [26] HDAC6 in Diseases of Cognition and of Neurons
    LoPresti, Patrizia
    CELLS, 2021, 10 (01) : 1 - 15
  • [27] HDAC6 score: to treat or not to treat?
    Hey, Joschka
    Prada, Maria Llamazares
    Plass, Christoph
    NATURE CANCER, 2023, 4 (02) : 156 - 158
  • [28] HDAC6 at the Intersection of Neuroprotection and Neurodegeneration
    d'Ydewalle, Constantin
    Bogaert, Elke
    Van Den Bosch, Ludo
    TRAFFIC, 2012, 13 (06) : 771 - 779
  • [29] QSAR Analysis of HDAC6 Inhibitors
    Tinkov, O. V.
    Grigorev, V. Yu.
    Grigoreva, L. D.
    MOSCOW UNIVERSITY CHEMISTRY BULLETIN, 2022, 77 (SUPPL 1) : S25 - S35
  • [30] HDAC6 score: to treat or not to treat?
    Joschka Hey
    Maria Llamazares Prada
    Christoph Plass
    Nature Cancer, 2023, 4 : 156 - 158